Wegovy maker Novo Nordisk said surging demand for its first weight loss pill has put it on track to beat trading forecasts. Shares in the Copenhagen-based pharmaceutical firm shot higher in early trading on Wednesday as a result. Novo Nordisk launched its Wegovy pill in January amid a battle in the weight loss drug market with Mounjaro manufacturer Eli Lilly . The Danish firm had seen sales and profits falter after demand for its injection treatments was hit hard by the rapid growth of rival drugs firms with weigh loss pills. It said the Wegovy pill’s launch was the strongest of any obesity drug in the US. Novo Nordisk reported more than two million prescriptions of the pill since its launch, with weekly prescriptions currently exceeding 200,000. Sales of the pill reach 2.26 billion Danish krone (£261 million) in the quarter to March 31, surpassing analyst predictions. The group’s adjusted net sales were nevertheless down 10% for the quarter, with adjusted operating profit down 15%.…